Bristol Myers Squibb (BMY) Expected to Announce Quarterly Earnings on Thursday

Bristol Myers Squibb (NYSE:BMY - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of $1.53 per share and revenue of $11.32 billion for the quarter.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter in the previous year, the firm earned ($4.40) EPS. The firm's revenue was down 5.6% compared to the same quarter last year. On average, analysts expect Bristol Myers Squibb to post $7 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY traded down $0.51 during trading hours on Friday, hitting $48.44. 11,836,611 shares of the company's stock were exchanged, compared to its average volume of 13,352,156. Bristol Myers Squibb has a 1-year low of $44.00 and a 1-year high of $63.33. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. The stock has a market capitalization of $98.57 billion, a price-to-earnings ratio of 18.14, a PEG ratio of 2.56 and a beta of 0.36. The company's 50-day moving average price is $47.63 and its 200-day moving average price is $52.70.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be paid a dividend of $0.62 per share. The ex-dividend date of this dividend is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.12%. Bristol Myers Squibb's dividend payout ratio is 92.88%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bristol Myers Squibb stock. Brighton Jones LLC lifted its position in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 33.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,728 shares of the biopharmaceutical company's stock after buying an additional 4,935 shares during the period. Brighton Jones LLC's holdings in Bristol Myers Squibb were worth $1,116,000 as of its most recent SEC filing. Institutional investors own 76.41% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Argus upgraded Bristol Myers Squibb to a "hold" rating in a research note on Friday, April 25th. UBS Group decreased their price objective on Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a report on Friday, April 11th. Jefferies Financial Group decreased their price objective on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a report on Wednesday, April 23rd. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, Piper Sandler began coverage on Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $58.53.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.